Anti-TNFRSF10B/TRAILR2/CD262 Antibody (Lexatumumab)
Catalog No.
F1047
Anti-TNFRSF10B/TRAILR2/CD262 Antibody (Lexatumumab)
Featured Products
Lexatumumab (HGS-ETR 2) is a human IgG1 monoclonal antibody that agonizes TRAIL receptor 2 (TRAIL-R2, DR5, APO-2). Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used in the study of malignant pleural mesothelioma (MPM).
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
143.48 kDa
Dry ice
845816-02-6
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
ETR2-ST01, HGS-ETR2, HGS1018
100 mM Pro 20 mM Arg pH 5.0. No preservative!
O14763
Human, Mouse
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human TNFRSF10B/TRAILR2 / CD262, Fc Tag at 2 ug/mL can bind lexatumumab
TNFRSF10B / TRAILR2 / CD262
Please avoid freeze-thaw cycles.